Key Takeaways RVMD reported a Q4 2025 loss of $1.86 per share, wider than estimates, with no revenues.Revolution Medicines expects 2026 operating expenses of $1.6B-$1.7B, including stock-based pay.Revolution Medicines advanced daraxonrasib into multiple late-stage studies in PDAC and NSCLC.Revolution Medicines (RVMD) reported a fourth-quarter 2025 loss of $1.86 per share, wider than the Zacks Consensus Estimate of a loss of $1.56. The company had incurred a loss of $1.12 in the year-ago quarter.Currently, R ...

Revolution Medicines (NasdaqGS:RVMD) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsAlan Sandler - Chief Development OfficerAnthony Mancini - Chief Global Commercialization OfficerAsthika Goonewardene - Managing Director, Equity ResearchJack Anders - CFOMark A. Goldsmith - Chairman and CEOPoorna Kannan - Biotech Equity Research AssociateRyan Aase - Senior Vice President of Corporate AffairsSteve Kelsey - President, Research and DevelopmentWei Lin - Chief Medical OfficerConference Ca ...

Revolution Medicines (NasdaqGS:RVMD) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsAlan Sandler - Chief Development OfficerAnthony Mancini - Chief Global Commercialization OfficerAsthika Goonewardene - Managing Director, Equity ResearchJack Anders - CFOMark A. Goldsmith - Chairman and CEOPoorna Kannan - Biotech Equity Research AssociateRyan Aase - Senior Vice President of Corporate AffairsSteve Kelsey - President, Research and DevelopmentWei Lin - Chief Medical OfficerConference Ca ...

Revolution Medicines (NasdaqGS:RVMD) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker15Good day, and thank you for standing by. Welcome to Revolution Medicines' fourth quarter 2025 earnings conference call. After the speaker's presentation, there will be a question-and-answer session. To ask a question during your session, you will need to press star 11 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 aga ...

On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026Continues to advance broad late-stage pipeline, with five ongoing Phase 3 trials and three additional Phase 3 trials planned to initiate in 2026Expects to substantially complete enrollment in RASolve 301, a Phase 3 trial of daraxonrasib in previously treated NSCLC, this yearInitiated RASolute 305, the first Phase 3 trial for zoldonrasib, in first line metastatic PDAC harboring a RAS G12 ...

Summit Therapeutics (NasdaqGM:SMMT) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Company ParticipantsAllen Yang - Chief R&D Strategy OfficerDave Gancarz - Chief Business and Strategy OfficerJosh Schimmer - Senior Managing Director and Leader in Biotechnology Equity ResearchMaky Zanganeh - Co-CEO and PresidentManmeet S. Soni - COO and CFOMark Schwartz - Vice ChairmanRobert Duggan - Co-Chief Executive Officer and Chairman of the BoardConference Call ParticipantsAsthika Goonewardene - Managing Director ...

Summit Therapeutics (NasdaqGM:SMMT) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Speaker10Good afternoon, welcome to Summit, Summit Therapeutics Q4 and year-end 2025 earnings call. All participants will be in listen-only mode until the question and answer session portion of this call. We do not expect any technical difficulties today. However, in the event that we lose the webcast connection and are unable to provide any updates, please wait up to 10 minutes for resolution. Please refer to the compan ...

Core Insights - Revolution Medicines (RVMD) shares fell 17% following a report that Merck (MRK) is no longer pursuing the acquisition of the company due to a disagreement over the buyout price [2][3][7] - The potential acquisition discussions may resume or attract new bidders, as both companies have not commented on the situation [3][7] - Merck was previously reported to be in talks to acquire RVMD for up to $32 billion, with a valuation range of approximately $28 billion to $32 billion being considered [4] Company Overview - Revolution Medicines is focused on developing novel drugs targeting the active, GTP-bound form of RAS proteins, referred to as RAS(ON) [5] - The lead candidate, daraxonrasib, is an investigational oral RAS(ON) multi-selective inhibitor aimed at treating various forms of cancer, including metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) [8][9] - RVMD is also developing other mutant-selective inhibitors, elironrasib and zoldonrasib, for specific RAS-bearing cancer cells [10] Pipeline Progress - Daraxonrasib is currently in late-stage studies, with data readouts expected from a phase III PDAC study in 2026 and additional phase III studies for first-line metastatic PDAC and NSCLC anticipated to begin later this year [9] - The RAS(ON) inhibitors are designed to overcome resistance mechanisms that limit the efficacy of first-generation RAS inhibitors available on the market [11] Market Performance - Over the past six months, RVMD shares have increased by 162.4%, significantly outperforming the industry average rise of 21.6% [6] - Revolution Medicines currently holds a Zacks Rank of 3 (Hold), while Alkermes (ALKS) is ranked 1 (Strong Buy) with a 26.6% increase in shares over the same period [12]

On Target to Outsmart Cancer 44th Annual JP Morgan Healthcare Conference January 12, 2026 © 2026 Revolution Medicines, Inc. 2 Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, availability of funding, abil ...

Core Insights - Merck (MRK) is in discussions to acquire Revolution Medicines (RVMD), with a potential valuation of up to $32 billion, although the deal is not yet finalized and may take several weeks to conclude [1][7] - RVMD's shares surged approximately 36% this week, reaching an all-time high of $105 per share following acquisition rumors, with a market capitalization of $20 billion [3] - The acquisition would enhance Merck's oncology pipeline by adding RVMD's lead candidate, daraxonrasib, which targets RAS mutations in cancers [6][10] Company Developments - Merck's shares have increased by 11.2%, but this is below the industry average increase of 21.0% [4] - The acquisition of RVMD is part of Merck's strategy to bolster its portfolio ahead of the patent expiration of its key drug, Keytruda, in 2028, which currently accounts for over 50% of its pharmaceutical sales [10][14] - Merck has been actively pursuing acquisitions, including the recent purchase of Cidara Therapeutics for $9.2 billion and Verona Pharma for around $10 billion, to diversify its offerings and mitigate revenue loss from Keytruda [12][13] Industry Context - Revolution Medicines is developing innovative drugs targeting the active form of RAS proteins, which are crucial in cancer treatment, with their RAS(ON) inhibitors designed to overcome resistance mechanisms seen in existing therapies [2][8] - The potential merger would mark a significant event in the biotech sector, being the largest deal since Pfizer's acquisition of Seagen for $43 billion in 2023 [3]